This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.89% per year. These returns cover a period from January 1, 1988 through March 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Should You Keep Your Portfolio Healthy with Biotech ETFs?
by Sanghamitra Saha
Biotech ETFs are riding high on research and developments and FDA approvals.
Biotech ETFs Soar on Gilead-Kite Deal
by Sanghamitra Saha
Gilead Sciences boosted the biotech ETF world on August 28 by announcing the buyout news of Kite Pharma.
How Kite Pharma Is Revolutionizing the Fight Against Cancer
by Eric Dutram
Immunotherapy is a hot corner of the biotech world. Learn how companies in this sector fight cancer in this podcast which features Dr. David Chang, the Chief Medical Officer of Kite Pharma. Do not miss it!
Stocks to Fight Cancer: Why Immunotherapy Is a Gamechanger
by Eric Dutram
This podcast takes a closer look at the world of cancer research, and in particular, that of immunotherapy. I have guest Brad Loncar on to discuss this market and a few promising candidates to watch in this area, check it out for more info on this interesting biotech segment!
4 Stocks & ETFs to Buy on Clovis' Positive Drug Data
by Sanghamitra Saha
Clovis Oncology clinical trial data has given a boost to the biotech sector and put these stocks and ETFs in focus.
Top and Flop ETFs of May 2017
by Sanghamitra Saha
Inside the best and worst performing ETFs of May 2017.
Trump Wins Healthcare Vote: ETFs to Watch
by Sweta Killa
The bill is expected to cut billions of dollars in health-care spending and result in millions of Americans going without health insurance.
Zacks Podcast Highlights: Immunotherapy Stocks 101: What Biotech Investors Need to Know Now
by Eric Dutram
Immunotherapy could be a hot area of the biotech world in 2017, what do investors need to know before diving into this market?
Biotech & Pharma ETFs to Suffer in 2017 Too?
by Sanghamitra Saha
What lies ahead for biotech and pharma ETFs in 2017?